Homepage

ABOUT US

Our Leadership

Our Leadership team is composed of seasoned professionals with a strong expertise in the orphan diseases and gene therapy field.

Our Board Members

Meet Vivet’s Board of Directors

Our Investors

Vivet is a private company with strong and committed investors.

Our Partners

Vivet is working with key and reliable long-term partners.

PIPELINE

PROGRAMS

INDICATION / TARGET

RESEARCH

POC

IND ENABLING

PHASE 1/2

PHASE 3

PARTNER

VTX-801

PHASE 3

Wilson’s disease

VTX-801 is an AAV-based gene therapy for Wilson’s disease. VTX-801 contains a corrective version of the ATP7B gene, which is malfunctioning in patients affected with Wilson’s disease, and is currently under clinical evaluation in a Phase 1/2 clinical safety and efficacy study (GATEWAY) with a 12-week readout. VTX-801 received US and EU Orphan Drug Designation (ODD).

VTX-802

POC

PFIC 2

VTX-802 is an AAV-based gene therapy for patients with Progressive Familial Intrahepatic Cholestasis Type 2. It delivers a codon-optimized version of the BSEP gene to the liver and is currently under preclinical testing.

VTX-803

PHASE 1/2

PFIC 3

VTX-803 is an AAV-based gene therapy for patients with Progressive Familial Intrahepatic Cholestasis Type 3. It delivers a codon-optimized version of the MDR3 gene to the liver and is currently under preclinical testing/IND enabling studies. VTX-803 received US and EU Orphan Drug Designation (ODD).

VTX-804

POC

Citrullinemia Type 1

VTX-804 is an AAV-based gene therapy for patients affected by Citrullinemia Type 1. It delivers a codon-optimized version of the ASS1 gene to the liver and is currently under preclinical testing.

VTX-805

RESEARCH

Undisclosed

Undisclosed.

VTX-PSM

POC

Sustained Expression

VTX-PSM is a non-integrative viral-based technology aimed to allow sustainability of expression in growing organs and tissues. It allows, without integration into the genome, to replicate the transgene during the mitosis. It is currently under preclinical testing.

VTX-PID

IND ENABLING

NAbs depletion

VTX-PID is a technology aimed to deplete Neutralizing Antibodies (NAbs) levels for a given AAV serotype, to a level allowing proper AAV transduction and therefore desired efficacy. VTX-PID is developed both for patients presenting NAbs because of a previous infection and therefore non eligible for gene therapy; and for patients in need of gene therapy re-administration in case of loss of efficacy.

OUR INVESTORS

Strong and Committed Investors

Vivet Therapeutics has investors from both sides of the ocean, bringing strong support, network and long-term commitment.

5

gene therapy Programs

2

innovation Technologica Platforms

26

dedicated Employees

20

years of cumulated Experience

NEWS

EVENTS

Vivet will be attending and presenting during the 6th annual Gene Therapy for Rare Disorders in Boston.

https://genetherapy-conference.com/

2022 has undoubtedly been a landmark year for the space with much-needed approvals in the summer marking the first time we have seen multiple approvals in a calendar year from the FDA. Gene Therapy for Rare Disorders 2023 will benchmark these breakthroughs, leverage strategic insights from recent success stories, and bring in-depth insights from experts

During the “Defining Value of Rare Gene Therapies” session, Vivet Therapeutic’s CEO & Co-Founder, Jean-Philippe Combal, will take part in the following panel discussion: “Navigating a Competitive Market & Establishing a Differentiated Product” (March 21, 2pm EST).

Topics to be discussed in this panel discussion will include:

👉 Exploring precompetitive collaboration to support progress to approval

👉 Navigating landscapes where multiple gene therapies are being developed for a specific disease

👉 Understanding value demonstration where standard of care exists and use of RWD to better understand disease severity

 
Vivet will be attending and presenting at the EPA World Congress in Amsterdam – March 21-23, 2023.

➡️ https://www.terrapinn.com/conference/pharma-pricing/agenda.stm

Thomas Daniel-Robin, Vivet Therapeutic’s BD Director, will take part in the HTA session and give the following presentation: “Healthcare databases versus current practice – gaps in information for patients, payers and physicians in Wilson Disease” (March 21, 4.25-5.30pm CET).

Topics to be discussed on the potential of national healthcare databases will include:

👉 Generating Real World Data for Rare Diseases: large cohorts and long-term follow-up

👉 Identifying data gaps between Real World Data and current practice: what can and cannot be captured by physicians and patients

👉 Finding the unexpected and understanding the value of enriched studies
From November 14th to 17th, Vivet will be attending and sharing our gene therapy expertise at the World Orphan Drug Congress 2022 in Sitjes (Spain).

Anne Douar, Vivet Therapeutics Chief Development Officer, will take part in the panel «Developing gene therapies for rare disease patients » on November 15 at 2 pm. She will also be a panel speaker on “Key considerations on cell & gene therapy manufacturing for commercialization” on November 17 at 10:10 am

Jean-Philippe Combal, Vivet Therapeutics Co-Founder and CEO, will participate in the panel “Designing first in human gene therapy clinical trials”, discussing gene therapy platform approaches for potential re-dosing strategy on November 15 at 3:10 pm

Contact Us
VIVET THERAPEUTICS

  • 80 Boulevard Haussmann
    75008 Paris, FRANCE
  • Av. de Pío XII, 55
    31008 Pamplona Spain
  • info@vivet-therapeutics.com